Patents by Inventor Nanette Que-Gewirth

Nanette Que-Gewirth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reversible platelet inhibition
    Patent number: 9873727
    Abstract: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: January 23, 2018
    Assignee: Duke University
    Inventors: Bruce A. Sullenger, Shahid Nimjee, Sabah Oney, Nanette Que-Gewirth
  • REVERSIBLE PLATELET INHIBITION
    Publication number: 20160289297
    Abstract: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.
    Type: Application
    Filed: July 28, 2014
    Publication date: October 6, 2016
    Applicant: DUKE UNIVERSITY
    Inventors: Bruce A. Sullenger, Shahid Nimjee, Sabah Oney, Nanette Que-Gewirth
  • Reversible platelet inhibition
    Patent number: 8790924
    Abstract: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: July 29, 2014
    Assignee: Duke University
    Inventors: Bruce A. Sullenger, Shahid Nimjee, Sabah Oney, Nanette Que-Gewirth
  • REVERSIBLE PLATELET INHIBITION
    Publication number: 20120264815
    Abstract: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.
    Type: Application
    Filed: November 14, 2011
    Publication date: October 18, 2012
    Applicant: DUKE UNIVERSITY
    Inventors: Bruce A. SULLENGER, Shahid Nimjee, Sabah Oney, Nanette Que-Gewirth
  • REVERSIBLE PLATELET INHIBITION
    Publication number: 20110118187
    Abstract: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 19, 2011
    Inventors: Bruce Sullenger, Shahid Nimjee, Sabah Oney, Nanette Que-Gewirth